Interferon beta-1a

Avonex(interferon beta-1a)

Avonex, Rebif (interferon beta-1a) is a protein pharmaceutical. Interferon beta-1a was first approved as Avonex on 1996-05-17. It is used to treat multiple sclerosis in the USA. It has been approved in Europe to treat multiple sclerosis.

Download report

Favorite

Top 200 Pharmaceuticals by Retail Sales

Events Timeline

Commercial

Clinical

Drug

Target

Variants

Financial

Trends

Safety

Events Timeline

YTD

Max

Events

FDA approval date

EMA approval date

Patent expiration date

Study first post date

Last update post date

Start date

Primary completion date

Completion date

Results first post date

Mock data
Subscribe for the real data

Commercial

Therapeutic Areas

Therapeutic Area	MeSH
nervous system diseases	D009422
immune system diseases	D007154

Trade Name

FDA

EMA

Avonex, Rebif (discontinued: Avonex)

Drug Products

FDA

EMA

Reference product - 351(a)

Interchangeable product - 351(k)

Biosimilar product - 351(k)

Interferon beta-1a

Tradename	Proper name	Company	Number	Date	Products
Avonex	interferon beta-1a	Biogen	N-103628 RX	2003-05-28	2 products
Rebif	interferon beta-1a	EMD Serono	N-103780 RX	2002-03-07	6 products

Show 1 discontinued

Labels

FDA

EMA

Brand Name	Status	Last Update
avonex	Biologic Licensing Application	2016-03-31
avonex avonex avonex pen	Biologic Licensing Application	2020-12-16
avonex avonex pen	Biologic Licensing Application	2023-07-31
rebif	Biologic Licensing Application	2010-01-14
rebif rebif rebidose	Biologic Licensing Application	2023-08-04

Indications

FDA

EMA

Indication	Ontology	MeSH	ICD-10
multiple sclerosis	EFO_0003885	D009103	G35

Agency Specific

FDA

EMA

Expiration	Code
interferon beta-1a, Avonex, Biogen Inc.
2103-05-17	Orphan excl.

Patent Expiration

No data

ATC Codes

L: Antineoplastic and immunomodulating agents

— L03: Immunostimulants

— L03A: Immunostimulants

— L03AB: Interferons

— L03AB07: Interferon beta-1a

HCPCS

Code	Description
J1826	Injection, interferon beta-1a, 30 mcg
Q3027	Injection, interferon beta-1a, 1 mcg for intramuscular use
Q3028	Injection, interferon beta-1a, 1 mcg for subcutaneous use

Clinical

Clinical Trials

246 clinical trials

View more details

Mock data
Subscribe for the real data

Indications Phases 4

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Multiple sclerosis	D009103	EFO_0003885	G35	10	30	50	43	72	202
Sclerosis	D012598	—	—	4	28	50	40	61	180
Relapsing-remitting multiple sclerosis	D020529	EFO_0003929	—	3	14	32	29	29	106
Covid-19	D000086382	—	—	—	4	7	2	4	16
Syndrome	D013577	—	—	—	—	2	1	—	3
Myelitis	D009187	—	—	—	1	—	2	—	3
Neuritis	D009443	—	—	—	—	—	2	—	2
Optic neuritis	D009902	EFO_0007405	H46	—	—	—	2	—	2
Erythema	D004890	HP_0010783	L53.9	—	—	—	1	—	1
Transverse myelitis	D009188	—	G37.3	—	—	—	1	—	1

Show 2 more

Indications Phases 3

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Coronavirus infections	D018352	EFO_0007224	B34.2	—	1	3	—	1	4
Respiratory distress syndrome	D012128	EFO_1000637	J80	—	—	1	—	1	2
Coronavirus	D017934	—	—	—	1	1	—	1	2
Sars-cov-2	D000086402	—	—	—	1	1	—	—	2
Severe acute respiratory syndrome	D045169	EFO_0000694	J12.81	—	—	2	—	—	2
Pneumonia	D011014	EFO_0003106	—	—	—	1	—	—	1
Acute lung injury	D055371	EFO_0004610	—	—	—	1	—	—	1
Newborn respiratory distress syndrome	D012127	—	P22	—	—	1	—	—	1
Hepatitis c	D006526	—	B19.2	—	—	1	—	—	1
Chronic hepatitis c	D019698	EFO_0004220	B18.2	—	—	1	—	—	1

Show 3 more

Indications Phases 2

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Ulcerative colitis	D003093	EFO_0000729	K51	—	3	—	—	—	3
Colitis	D003092	EFO_0003872	K52.9	—	3	—	—	—	3
Ulcer	D014456	MPATH_579	—	—	3	—	—	—	3
Infections	D007239	EFO_0000544	—	—	2	—	—	—	2
Asthma	D001249	EFO_0000270	J45	—	2	—	—	—	2
Chronic obstructive pulmonary disease	D029424	EFO_0000341	J44.9	—	1	—	—	—	1
Obstructive lung diseases	D008173	HP_0006536	—	—	1	—	—	—	1
Multiple organ failure	D009102	EFO_1001373	—	—	1	—	—	—	1
Respiratory tract infections	D012141	—	J06.9	—	1	—	—	—	1
Alzheimer disease	D000544	EFO_0000249	F03	—	1	—	—	—	1

Show 25 more

Indications Phases 1

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Healthy volunteers/patients	—	—	—	11	—	—	—	—	11
Pharmacokinetics	D010599	—	—	1	—	—	—	—	1
Pharmacological phenomena	D000069437	—	—	1	—	—	—	—	1
Therapeutic equivalency	D013810	—	—	1	—	—	—	—	1
Renal insufficiency	D051437	HP_0000083	N19	1	—	—	—	—	1
Stroke	D020521	EFO_0000712	I63.9	1	—	—	—	—	1

Indications Without Phase

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Acute kidney injury	D058186	HP_0001919	N17	—	—	—	—	1	1
Iatrogenic disease	D007049	—	—	—	—	—	—	1	1
Chronic progressive multiple sclerosis	D020528	EFO_0003840	—	—	—	—	—	1	1
Injection site reaction	D000075662	—	—	—	—	—	—	1	1
Atrophy	D001284	—	—	—	—	—	—	1	1
Exercise	D015444	EFO_0000483	—	—	—	—	—	1	1
Metabolic bone diseases	D001851	HP_0000938	—	—	—	—	—	1	1
Prenatal exposure delayed effects	D011297	—	—	—	—	—	—	1	1
Pregnancy	D011247	EFO_0002950	Z33.1	—	—	—	—	1	1
Body weight	D001835	EFO_0004338	—	—	—	—	—	1	1

Epidemiology

Epidemiological information for investigational and approved indications

View more details

Drug

General

Drug common name	Interferon beta-1a
INN	—
Description	Interferon beta precursor (IFN-beta) (Fibroblast interferon)
Classification	Protein
Drug class	—
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)	—